
|Videos|March 29, 2021
Are Combinations the Answer in Metastatic RCC?
Author(s)Targeted Oncology
Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5








































